Grufity logo
Grufity logo

Latest Rhenman & Partners Asset Management AB Stock Portfolio

$1.06Billion | No. of Holdings #99

Rhenman & Partners Asset Management AB Performance

2026 Q2+8.53%
YTD+1.87%
2025+14.42%

About Rhenman & Partners Asset Management AB and 13F Hedge Fund Stock Holdings

On 2026-08-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, Rhenman & Partners Asset Management AB reported an equity portfolio of $1.1 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Rhenman & Partners Asset Management AB are UNH, CVS, . The fund has invested 3.7% of it's portfolio in UNITED HEALTH GROUP INC and 2.7% of portfolio in CVS HEALTH CORP. <br><br> The fund managers got completely rid off ADAPTIVE BIOTECHNOLOGIES COR (ADPT), IQVIA HLDGS INC (IQV) and NUVALENT INC (NUVL) stocks. They significantly reduced their stock positions in VEEVA SYS INC (VEEV), MADRIGAL PHARMACEUTICALS INC (MDGL) and DOXIMITY INC (DOCS). Rhenman & Partners Asset Management AB opened new stock positions in ASTRAZENECA PLC, MERCK & CO INC (MRK) and JOHNSON & JOHNSON (JNJ). The fund showed a lot of confidence in some stocks as they added substantially to ALIGN TECHNOLOGY INC (ALGN), DANAHER CORPORATION (DHR) and BRIGHTSPRING HEALTH SVCS INC.
Rhenman & Partners Asset Management AB Equity Portfolio Value
Last Reported on: 13 Aug, 2026
$1.06Billion
  as of Aug 13, 2026

Rhenman & Partners Asset Management AB Annual Return Estimates Vs S&P 500

Our best estimate is that Rhenman & Partners Asset Management AB made a return of 8.53% in the last quarter. In trailing 12 months, it's portfolio return was 16.08%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
astrazeneca plc28,480,800
merck & co inc27,434,800
johnson & johnson18,412,800
centene corp del15,662,400
dexcom inc10,776,000
spyre therapeutics inc10,591,500
oruka therapeutics inc7,613,600
erasca inc6,393,680
New stocks bought by Rhenman & Partners Asset Management AB

Additions

Ticker% Inc.
align technology inc740
danaher corporation344
brightspring health svcs inc231
agilent technologies inc200
insulet corp200
nektar therapeutics139
charles riv labs intl inc120
nurix therapeutics inc118
Additions to existing portfolio by Rhenman & Partners Asset Management AB

Reductions

Ticker% Reduced
veeva sys inc-79.72
madrigal pharmaceuticals inc-66.53
doximity inc-58.59
alnylam pharmaceuticals inc-50.09
waystar hldg corp-47.87
regeneron pharmaceuticals-43.06
oscar health inc-40.61
ionis pharmaceuticals inc-35.52
Rhenman & Partners Asset Management AB reduced stake in above stock

Sold off

Ticker$ Sold
esperion therapeutics inc ne-2,698,900
adaptive biotechnologies cor-9,993,600
compass therapeutics inc-608,948
immunocore hldgs plc-2,584,580
nuvalent inc-8,318,940
apogee therapeutics inc-6,312,750
iqvia hldgs inc-9,038,620
ascendis pharma a/s-3,430,950
Rhenman & Partners Asset Management AB got rid off the above stocks

Sector Distribution

Rhenman & Partners Asset Management AB has about 87.9% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare87.9
Others12.1

Market Cap. Distribution

Rhenman & Partners Asset Management AB has about 64% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • MID-CAP
  • MEGA-CAP
  • UNALLOCATED
  • SMALL-CAP
  • MICRO-CAP
Category%
LARGE-CAP49.3
MID-CAP17.6
MEGA-CAP14.7
UNALLOCATED10.8
SMALL-CAP6.3
MICRO-CAP1.3

Stocks belong to which Index?

About 72% of the stocks held by Rhenman & Partners Asset Management AB either belong to S&P 500 or RUSSELL 2000 index.

  • S&P 500
  • Others
  • RUSSELL 2000
Index%
S&P 50044.6
Others27.9
RUSSELL 200027.4
Top 5 Winners (%)%
OSCR
oscar health inc
118.5 %
anteris technologies global
73.1 %
RLAY
relay therapeutics inc
62.1 %
GH
guardant health inc
56.0 %
AXSM
axsome therapeutics inc.
44.5 %
Top 5 Winners ($)$
UNH
united health group inc
10.1 M
CVS
cvs health corp
9.7 M
OSCR
oscar health inc
9.0 M
LLY
lilly eli & co
7.8 M
GH
guardant health inc
7.5 M
Top 5 Losers (%)%
INSM
insmed inc
-34.0 %
BSX
boston scientific corp
-27.5 %
PODD
insulet corp
-20.1 %
ATEC
alphatec hldgs inc
-19.0 %
REGN
regeneron pharmaceuticals
-15.1 %
Top 5 Losers ($)$
BSX
boston scientific corp
-10.8 M
INSM
insmed inc
-8.9 M
REGN
regeneron pharmaceuticals
-5.6 M
ISRG
intuitive surgical inc
-2.3 M
GILD
gilead sciences inc
-2.3 M

Rhenman & Partners Asset Management AB Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB has 99 stocks in it's portfolio. About 25.1% of the portfolio is in top 10 stocks. BSX proved to be the most loss making stock for the portfolio. UNH was the most profitable stock for Rhenman & Partners Asset Management AB last quarter.

$1.06BTotal Value
107Positions
13 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Rhenman & Partners Asset Management AB, last reported on 13 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ASND
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
Rhenman & Partners Asset Management AB's holding in Ascendis Pharma A/S over time
0%0.00
$0.00
0%
decreased 100 percentsold off